Patents by Inventor Anjali A. Hirani

Anjali A. Hirani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Loteprednol etabonate nanoparticles in thermoreversible gels for enhanced therapeutics
    Patent number: 10973776
    Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: April 13, 2021
    Assignee: University of South Florida
    Inventors: Vijaykumar Bhadabhai Sutariya, Anjali A. Hirani, Yashwant V. Pathak
  • Nanoparticles in thermoreversible gels for enhanced therapeutics
    Patent number: 10729663
    Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: August 4, 2020
    Assignee: University of South Florida
    Inventors: Vijaykumar Bhadabhai Sutariya, Anjali A. Hirani, Yashwant V. Pathak